title: The amelioration effect of tranexamic acid in wrinkles induced by skin dryness.
abstract: Tranexamic acid (trans-4-aminomethylcyclohexanecarboxylic acid) is a medical amino acid widely used as an anti-inflammatory and a whitening agent. This study examined the effect of tranexamic acid administration in wrinkle formation following skin dryness. We administered tranexamic acid (750mg/kg/day) orally for 20 consecutive days to Naruto Research Institute Otsuka Atrichia (NOA) mice, which naturally develop skin dryness. In these NOA mice, deterioration of transepidermal water loss (TEWL), generation of wrinkles, decrease of collagen type I, and increases in mast cell proliferation and tryptase and matrix metalloproteinase (MMP-1) release were observed. However, these symptoms were improved by tranexamic acid treatment. Moreover, the increase in the β-endorphin level in the blood and the expression of μ-opioid receptor on the surface of fibroblasts increased by tranexamic acid treatment. In addition, when the fibroblasts induced by tranexamic acid treatment were removed, the amelioration effect by tranexamic acid treatment was halved. On the other hand, tranexamic acid treated NOA mice and mast cell removal in tranexamic acid treated NOA mice did not result in changes in the wrinkle amelioration effect. Additionally, the amelioration effect of mast cell deficient NOA mice was half that of tranexamic acid treated NOA mice. These results indicate that tranexamic acid decreased the proliferation of mast cells and increases the proliferation of fibroblasts, subsequently improving wrinkles caused by skin dryness.
authors.affiliation: Department of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagakicho, Suzuka, Mie 513-8670, Japan. Electronic address: hiramoto@suzuka-u.ac.jp.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Hiramoto
authors.affiliation: R&D Department, Daiichi Sankyo healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo 103-8234, Japan.
authors.forename: Daijiro
authors.initials: D
authors.lastname: Sugiyama
authors.affiliation: R&D Department, Daiichi Sankyo healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo 103-8234, Japan.
authors.forename: Yumi
authors.initials: Y
authors.lastname: Takahashi
authors.affiliation: R&D Department, Daiichi Sankyo healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo 103-8234, Japan.
authors.forename: Eiichi
authors.initials: E
authors.lastname: Mafune
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000634:Aminoquinolines / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002738:Chloroquine / Q000494:pharmacology; D003345:Corticosterone / Q000097:blood; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008407:Mast Cells / Q000187:drug effects; D051379:Mice; D017450:Receptors, Opioid, mu / Q000378:metabolism; D015595:Skin Aging / Q000187:drug effects*; D012871:Skin Diseases / Q000097:blood / Q000188:drug therapy*; D019089:Stem Cell Factor / Q000276:immunology; D014148:Tranexamic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D014870:Water Loss, Insensible / Q000187:drug effects; D001615:beta-Endorphin / Q000097:blood
chemical_list: D000634:Aminoquinolines; D000906:Antibodies; D001549:Benzamides; C433236:N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide; D017450:Receptors, Opioid, mu; D019089:Stem Cell Factor; D007073:Immunoglobulin E; D001615:beta-Endorphin; D014148:Tranexamic Acid; D002738:Chloroquine; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone
keywords: Collagen type I; Fibroblast; Mast cell; Tranexamic acid; Transepidermal water loss; Wrinkle